About
Kalexo Bio develops dual-targeting siRNA therapeutics aimed at genetically validated drivers of cardiovascular disease to provide durable lipid management and reduce atherosclerotic cardiovascular events.
Explore Kalexo Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.